According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical business. It focuses on finding and developing tiny particle medicine prospects to treat cancer cells. The Company‘s products under different phases of growth include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and also Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “
Several various other equities research experts likewise lately talked about the business. Noble Financial editioned a “buy” rating and released a $11.00 price purpose on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their cost target on Onconova Therapeutics from $29.00 to $12.00 and also set a “buy” score on the stock in a research note on Tuesday, September 28th.
NASDAQ: ONTX opened up at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and a twelve month high of $28.95. Business has a 50 day moving average rate of $2.90 as well as a two-hundred day moving typical rate of $4.16. The company has a market cap of $46.76 million, a P/E proportion of -1.82 and a beta of 1.67.
Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly revenues results on Thursday, November 11th. The biopharmaceutical company reported ($ 0.22) profits per share for the quarter, topping experts’ consensus price quotes of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% as well as a negative net margin of 8,294.27%. The firm had earnings of $0.06 million during the quarter, compared to the agreement quote of $0.06 million. Throughout the same quarter in the prior year, the firm uploaded ($ 0.45) EPS. En masse, research experts forecast that Onconova Therapeutics will upload -1.18 EPS for the present year.
A variety of hedge funds have just recently bought and sold shares of ONTX. GSA Funding Partners LLP purchased a brand-new setting in Onconova Therapeutics throughout the third quarter worth $922,000. Hudson Bay Capital Management LP acquired a new position in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC acquired a brand-new position in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC acquired a new position in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP got a brand-new placement in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds and also various other institutional investors own 13.36% of the business’s stock.
Concerning Onconova Therapeutics
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which participates in the identification as well as advancement of oncology therapeutics. It concentrates on uncovering as well as developing small molecule drug prospects to treat cancer cells. The business was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA
. Obtain a cost-free duplicate of the Zacks research report on Onconova Therapeutics (ONTX).
For more details regarding research offerings from Zacks Investment Research, visit Zacks.com.
This instant news alert was produced by narrative scientific research technology and also economic data from Market in order to offer viewers with the fastest and most accurate coverage. This story was examined by Market’s content group before publication.
SHOULD YOU INVEST $1,000 IN ONCONOVA THERAPEUTICS RIGHT NOW?
Prior to you consider Onconova Therapeutics, you’ll wish to hear this.
Market keeps an eye on Wall Street’s premier as well as ideal executing research experts as well as the stocks they advise to their customers each day. Market has recognized the five stocks that top experts are silently murmuring to their customers to purchase currently before the more comprehensive market catches on … as well as Onconova Therapeutics had not been on the listing.
While Onconova Therapeutics presently has a “Buy” rating among analysts, premier experts believe these five stocks are better buys.